Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Restructuring & Asset Impairment Expense by Year
Restructuring & Asset Impairment Expense (legacy) ($M) ($M)
Amgen Restructuring & Asset Impairment Expense: $114M in FY2015. No newer figure appears in the documents we track.
Latest, FY2015
114
Period ended Dec 31, 2015
Change on a year earlier
–
History
1 years
Since FY2015
Sources
1
Form 10-K (filed 2018-02-13)
Where the FY2015 figure comes from
Source: Form 10-K (filed 2018-02-13) ↗
Reported in Form 10-K Restructuring Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Restructuring & Asset Impairment Expense (legacy) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2015 | Dec 31, 2015 | 114 | – | Form 10-K (filed 2018-02-13) ↗ |
Cite this data
StockData. (2026). Amgen Restructuring & Asset Impairment Expense ($M), annual FY2015–FY2015 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/restruct-impair-exp
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.